Loading...
•
Dec 31, 2025
Biohaven Q4 2025 Earnings Report
Biohaven reported Q4 2025 results reflecting strategic portfolio prioritization and continued investment in late-stage programs, with reduced operating expenses year-over-year.
Key Takeaways
Biohaven reported a net loss of 145555000 for Q4 2025 as the company advanced key late-stage programs while implementing cost optimization measures. R&D expenses declined year-over-year to 121945000, and cash, cash equivalents and marketable securities totaled 319137000 at quarter end.
Net loss was 145555000, or 1.21 per share.
R&D expenses declined to 121945000 from 167473000 year-over-year.
G&A expenses were 20789000 for the quarter.
Cash, cash equivalents and marketable securities totaled 319137000 at December 31, 2025.
Forward Guidance
Biohaven is prioritizing three late-stage programs in degraders, epilepsy, and obesity while executing cost optimization measures and advancing pivotal trials expected to deliver topline data in 2026.
Positive Outlook
- Initiated strategic cost optimization in Q4 2025.
- Pivotal degrader trials expected to begin in 2026.
- Opakalim pivotal topline data expected in 2H 2026.
- Phase 2 obesity study initiated in Q4 2025.
- Strong liquidity position entering 2026.
Challenges Ahead
- Continued significant net losses.
- High R&D spend despite reductions.
- Dependence on successful clinical outcomes.
- Ongoing capital requirements.
- Exposure to clinical and regulatory risk.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...